CrystecPharma opens R&D facility in Haimen City, China

Haimen Biopharmaceutical Technology Entrepreneurship Park

Facility will support UK-based crystal and particle engineering specialist's existing Chinese subsidiary to expand product development services

The new facility at Haimen Science and Technology Park was established after Crystec participated in the Yangtze Delta Advanced Drug Development platform, jointly funded by the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, and the Haimen government.

The platform, which has received GBP 550 million equivalent in investment, is dedicated to accelerating pharmaceutical product innovation underpinned by pharmaceutical excipients and drug delivery technologies.

Crystec said its proprietary mSAS supercritical fluid technology will play a key role in enabling the development of new therapeutics, creation of value-added medicines, and in simplification of formulations and manufacturing processes.

“This cutting-edge research facility will enhance our capacity to support clients across China and the rest of the world, and will provide opportunities to achieve rapid transition from proof of concept studies to delivering clinical material for human trials in China,” said Dr. Qun Shao, Crystec’s Chief Operations Officer.

The new Haimen facility will support Crystec’s ongoing development strategy in China, working alongside Crystec’s existing China subsidiary, Tianjin Crystec Pharmaceutical Technology, and its UK headquarters in Bradford, UK, to expand and enhance product development services offered across the region and globally.